tiprankstipranks
Trending News
More News >
Relay Therapeutics (RLAY)
NASDAQ:RLAY
US Market
Advertisement

Relay Therapeutics (RLAY) Stock Statistics & Valuation Metrics

Compare
505 Followers

Total Valuation

Relay Therapeutics has a market cap or net worth of $610.34M. The enterprise value is -$30.02M.
Market Cap$610.34M
Enterprise Value-$30.02M

Share Statistics

Relay Therapeutics has 172,411,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding172,411,400
Owned by Insiders2.68%
Owned by Institutions52.58%

Financial Efficiency

Relay Therapeutics’s return on equity (ROE) is -0.43 and return on invested capital (ROIC) is -45.08%.
Return on Equity (ROE)-0.43
Return on Assets (ROA)-0.39
Return on Invested Capital (ROIC)-45.08%
Return on Capital Employed (ROCE)-0.45
Revenue Per Employee38.64K
Profits Per Employee-1.30M
Employee Count259
Asset Turnover0.01
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Relay Therapeutics is ―. Relay Therapeutics’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value0.76
Price to FCF
Price to Operating Cash Flow-2.24
PEG Ratio

Income Statement

In the last 12 months, Relay Therapeutics had revenue of 10.01M and earned -337.71M in profits. Earnings per share was -2.36.
Revenue10.01M
Gross Profit-305.43M
Operating Income-372.47M
Pretax Income-337.71M
Net Income-337.71M
EBITDA-380.21M
Earnings Per Share (EPS)-2.36

Cash Flow

In the last 12 months, operating cash flow was -261.42M and capital expenditures -637.00K, giving a free cash flow of -262.06M billion.
Operating Cash Flow-261.42M
Free Cash Flow-262.06M
Free Cash Flow per Share-1.52

Dividends & Yields

Relay Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta2.34
52-Week Price Change-47.42%
50-Day Moving Average3.50
200-Day Moving Average3.71
Relative Strength Index (RSI)53.17
Average Volume (3m)2.42M

Important Dates

Relay Therapeutics upcoming earnings date is Nov 5, 2025, Before Open (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend Date

Financial Position

Relay Therapeutics as a current ratio of 15.95, with Debt / Equity ratio of 5.14%
Current Ratio15.95
Quick Ratio15.95
Debt to Market Cap0.00
Net Debt to EBITDA0.20
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Relay Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Relay Therapeutics EV to EBITDA ratio is -1.35, with an EV/FCF ratio of -2.04.
EV to Sales51.25
EV to EBITDA-1.35
EV to Free Cash Flow-2.04
EV to Operating Cash Flow-2.06

Balance Sheet

Relay Therapeutics has $113.94M in cash and marketable securities with $34.18M in debt, giving a net cash position of -$79.76M billion.
Cash & Marketable Securities$113.94M
Total Debt$34.18M
Net Cash-$79.76M
Net Cash Per Share-$0.46
Tangible Book Value Per Share$5.43

Margins

Gross margin is -15.04%, with operating margin of -3722.07%, and net profit margin of -3374.72%.
Gross Margin-15.04%
Operating Margin-3722.07%
Pretax Margin-3374.72%
Net Profit Margin-3374.72%
EBITDA Margin-3799.44%
EBIT Margin-3854.04%

Analyst Forecast

The average price target for Relay Therapeutics is $12.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$12.88
Price Target Upside260.78% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast-76.27%
EPS Growth Forecast22.77%

Scores

Smart Score3
AI Score55
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis